Ryo Utsunomiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryo Utsunomiya has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Xiuju Dai
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan
5 shared publications - Hideki Mori
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan
4 shared publications - Jun Muto
Department of Dermatology Ehime University Graduate School of Medicine Ehime Japan
4 shared publications - Ken Shiraishi
Department of Dermatology Ehime University Graduate School of Medicine Ehime Japan
4 shared publications - Koji Sayama
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan
4 shared publications - Masamoto Murakami
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan
4 shared publications
Latest Publications
- 22 April 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (6) , 994-1005
EGFR ligands synergistically increase IL‐17A‐induced expression of psoriasis signature genes in human keratinocytes via IκBζ and Bcl3
Various epidermal growth factor receptor (EGFR) ligands are highly expressed in the epidermis of psoriasis lesions, and abnormal EGFR activation appears to be involved in the pathogenesis of psoriasis. However, how EGFR signaling contributes to the development of psoriasis is unclear. Interleukin (IL)‐17A, a critical effector of the IL‐23/IL‐17A pathway, increases the expression of psoriasis signature genes in keratinocytes and plays an essential role in the pathogenesis of psoriasis by inducing IκBζ, a critical transcriptional regulator in psoriasis. In this study, we stimulated primary human keratinocytes with IL‐17A and various EGFR ligands to investigate whether EGFR ligands regulate the expression of psoriasis signature genes. In cultured normal human keratinocytes and a living skin equivalent, EGFR ligands did not induce psoriasis‐related gene expression, but significantly enhanced the IL‐17A‐mediated induction of various psoriasis signature genes, including antimicrobial peptides, cytokines, and chemokines. This was dependent on an EGFR activation‐mediated synergistic increase in IL‐17A‐induced IκBζ expression and was partially mediated by the EGFR‐dependent upregulation of Bcl3. Therefore, EGFR ligands can act as synergistic agents of IL‐17A signaling by stimulating the epidermal production of psoriasis signature genes in psoriasis lesions. This study reveals a potential mechanism by which EGFR signaling contributes to the pathogenesis of psoriasis.
- 22 April 2022
- Published by Wiley in European Journal of Immunology
- Vol. 52 (6) , 994-1005
EGFR ligands synergistically increase IL‐17A‐induced expression of psoriasis signature genes in human keratinocytes via IκBζ and Bcl3
Various epidermal growth factor receptor (EGFR) ligands are highly expressed in the epidermis of psoriasis lesions, and abnormal EGFR activation appears to be involved in the pathogenesis of psoriasis. However, how EGFR signaling contributes to the development of psoriasis is unclear. Interleukin (IL)‐17A, a critical effector of the IL‐23/IL‐17A pathway, increases the expression of psoriasis signature genes in keratinocytes and plays an essential role in the pathogenesis of psoriasis by inducing IκBζ, a critical transcriptional regulator in psoriasis. In this study, we stimulated primary human keratinocytes with IL‐17A and various EGFR ligands to investigate whether EGFR ligands regulate the expression of psoriasis signature genes. In cultured normal human keratinocytes and a living skin equivalent, EGFR ligands did not induce psoriasis‐related gene expression, but significantly enhanced the IL‐17A‐mediated induction of various psoriasis signature genes, including antimicrobial peptides, cytokines, and chemokines. This was dependent on an EGFR activation‐mediated synergistic increase in IL‐17A‐induced IκBζ expression and was partially mediated by the EGFR‐dependent upregulation of Bcl3. Therefore, EGFR ligands can act as synergistic agents of IL‐17A signaling by stimulating the epidermal production of psoriasis signature genes in psoriasis lesions. This study reveals a potential mechanism by which EGFR signaling contributes to the pathogenesis of psoriasis.
- 19 January 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (8) , 2100-2108.e5
TSLP Impairs Epidermal Barrier Integrity by Stimulating the Formation of Nuclear IL-33/Phosphorylated STAT3 Complex in Human Keratinocytes
- 19 January 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (8) , 2100-2108.e5
TSLP Impairs Epidermal Barrier Integrity by Stimulating the Formation of Nuclear IL-33/Phosphorylated STAT3 Complex in Human Keratinocytes
- 1 January 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (1) , 136-144.e3
Nuclear IL-33 Plays an Important Role in IL-31‒Mediated Downregulation of FLG, Keratin 1, and Keratin 10 by Regulating Signal Transducer and Activator of Transcription 3 Activation in Human Keratinocytes
- 1 January 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (1) , 136-144.e3
Nuclear IL-33 Plays an Important Role in IL-31‒Mediated Downregulation of FLG, Keratin 1, and Keratin 10 by Regulating Signal Transducer and Activator of Transcription 3 Activation in Human Keratinocytes
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2646-2655.e6
Nuclear IL-33 Plays an Important Role in the Suppression of FLG, LOR, Keratin 1, and Keratin 10 by IL-4 and IL-13 in Human Keratinocytes
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2646-2655.e6
Nuclear IL-33 Plays an Important Role in the Suppression of FLG, LOR, Keratin 1, and Keratin 10 by IL-4 and IL-13 in Human Keratinocytes
- Open Access
- 13 May 2018
- Published by Wiley in Experimental Dermatology
- Vol. 27 (9) , 981-988
Heparinoid suppresses Der p‐inducedIL‐1β production by inhibitingERKand p38MAPKpathways in keratinocytes
Epidermal keratinocytes initiate skin inflammation by activating immune cells. The skin barrier is disrupted in atopic dermatitis (AD) and epidermal keratinocytes can be exposed to environmental stimuli, such as house dust mite (HDM) allergens. We showed previously thatHDMallergens activate theNLRP3 inflammasome of keratinocytes, thereby releasing pro‐inflammatory cytokines. Heparinoid is an effective moisturizer for atopic dry skin. However, a recent report showed that heparinoid treatment can improve inflammation of lichen planus. Therefore, we hypothesized that it acts on epidermal keratinocytes not only as a moisturizer, but also as a suppressant of the triggers of skin inflammation. We found thatHDMallergen‐induced interleukin (IL)‐1β release from keratinocytes was inhibited significantly by heparinoid pretreatment without affecting cell viability. However, heparinoid did not affect caspase‐1 release, suggesting that heparinoid did not affectHDMallergen‐induced inflammasome activation. Heparinoid treatment not only decreased intracellular levels of pro‐IL‐1β, but also suppressedIL‐1β messengerRNA(mRNA) expression in keratinocytes. Among the intracellular signalling pathways, the activation of extracellular signal‐regulated kinase and p38 pathways, which are required forIL‐1β expression in keratinocytes, was inhibited by heparinoid treatment. The inhibitory effect of heparinoid onIL‐1βmRNAexpression was also confirmed with living skin equivalents. Our results demonstrated that heparinoid suppresses the initiation of keratinocyte‐mediated skin inflammation.
- 13 May 2018
- Published by Wiley in Experimental Dermatology
- Vol. 27 (9) , 981-988
Open AccessHeparinoid suppresses Der p‐inducedIL‐1β production by inhibitingERKand p38MAPKpathways in keratinocytes
Epidermal keratinocytes initiate skin inflammation by activating immune cells. The skin barrier is disrupted in atopic dermatitis (AD) and epidermal keratinocytes can be exposed to environmental stimuli, such as house dust mite (HDM) allergens. We showed previously thatHDMallergens activate theNLRP3 inflammasome of keratinocytes, thereby releasing pro‐inflammatory cytokines. Heparinoid is an effective moisturizer for atopic dry skin. However, a recent report showed that heparinoid treatment can improve inflammation of lichen planus. Therefore, we hypothesized that it acts on epidermal keratinocytes not only as a moisturizer, but also as a suppressant of the triggers of skin inflammation. We found thatHDMallergen‐induced interleukin (IL)‐1β release from keratinocytes was inhibited significantly by heparinoid pretreatment without affecting cell viability. However, heparinoid did not affect caspase‐1 release, suggesting that heparinoid did not affectHDMallergen‐induced inflammasome activation. Heparinoid treatment not only decreased intracellular levels of pro‐IL‐1β, but also suppressedIL‐1β messengerRNA(mRNA) expression in keratinocytes. Among the intracellular signalling pathways, the activation of extracellular signal‐regulated kinase and p38 pathways, which are required forIL‐1β expression in keratinocytes, was inhibited by heparinoid treatment. The inhibitory effect of heparinoid onIL‐1βmRNAexpression was also confirmed with living skin equivalents. Our results demonstrated that heparinoid suppresses the initiation of keratinocyte‐mediated skin inflammation.